Stock Monitor: Impax Laboratories Post Earnings Reporting
LONDON, UK / ACCESSWIRE / April 02, 2018 / Active-Investors.com has just released a free research report on Assembly Biosciences, Inc. (NASDAQ: ASMB). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=ASMB as the Company's latest news hit the wire. On March 28, 2018, the Company announced that it will have planned poster presentation of the Phase-1b clinical trial of the Company's CpAM candidate, ABI-H0731, evaluating safety, tolerability, and antiviral activity in subjects with chronic HBV at The International Liver Congress™, the Annual Meeting of the European Association for the Study of the Liver (EASL) being held April 11-15, 2018, in Paris. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Impax Laboratories, Inc. (NASDAQ: IPXL), which also belongs to the Healthcare sector as the Company Assembly Biosciences. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/'symbol=IPXL
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Assembly Biosciences most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/'symbol=ASMB
The Company also announced publication of a late-breaker abstract, which will include the preliminary data available from 49 healthy volunteers and patients at the time of submission (February 2018). At EASL, Assembly intends to present an expanded dataset including three healthy subject cohorts and three HBV patient cohorts treated with ABI-H0731.
Phase-1b Study Objective: Identifying Minimal Dose that Produces Maximum Efficacy of ABI-H0731
Richard Colonno, PhD, Assembly's Executive Vice President and Chief Scientific Officer of Virology Operations, stated that the Company is pleased to report that initial results of its ongoing Phase-1b study of ABI-H0731 show an attractive safety profile and significant antiviral potency in both HBeAg positive and negative patients, with viral DNA reductions increasing with increasing dose levels. An important study objective is to identify the minimal dose that produces maximum efficacy of ABI-H0731.
Richard added that the Company believes it has identified the dose level sufficient to suppress cccDNA establishment and move forward into Phase-2a proof of concept studies this summer.
ABI-H0731 was Observed to be Generally Safe and Well Tolerated
Initial patient data from the ongoing Phase-1b study indicate that ABI-H0731 demonstrates potent antiviral activity with once daily dosing for 28 days, is generally safe and well tolerated, and exhibits increasing plasma exposures with increasing dose. At 100 mg per day, the lowest dose tested, HBV declines of 1.3 and 2.2 log10 IU/mL were observed in HBeAg positive and negative patients (respectively). Declines up to approximately 4 logs in HBeAg negative patients were observed following administration of 400 mg per day. HBV RNA reductions were generally proportional to reductions of plasma HBV DNA. No serious adverse events (AEs) and no dose limiting laboratory toxicities were observed. Over 60 healthy volunteers and patients have been dosed to date, with no dose limiting side effects.
About Hepatitis B Virus (HBV) Infection
Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver. It can cause both acute and chronic infections. Many people have no symptoms during the initial infection. Some develop a rapid onset of sickness with vomiting, yellowish skin, tiredness, dark urine, and abdominal pain. Often these symptoms last a few weeks and rarely does the initial infection result in death. Most of those with chronic disease have no symptoms; however, cirrhosis and liver cancer may eventually develop. The virus is transmitted by exposure to infectious blood or body fluids. Infection around the time of birth or from contact with other people's blood during childhood is the most frequent method by which hepatitis B is acquired in areas where the disease is common.
About Assembly Biosciences, Inc.
Founded in 2014, Assembly Biosciences, Inc. is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome. The Company has offices in Carmel, Indiana, and San Francisco, California.
Stock Performance Snapshot
March 29, 2018 - At Thursday's closing bell, Assembly Biosciences' stock fell 3.15%, ending the trading session at $49.14.
Volume traded for the day: 365.58 thousand shares, which was above the 3-month average volume of 171.82 thousand shares.
Stock performance in the last three-month - up 9.13%; previous six-month period - up 46.08%; past twelve-month period - up 93.92%; and year-to-date - up 8.60%
After last Thursday's close, Assembly Biosciences' market cap was at $1.03 billion.
The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry. This sector was up 0.5% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visithttp://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
